AI Article Synopsis
- Alopecia areata (AA) and nonsegmental vitiligo (NSV) are autoimmune skin diseases influenced by oxidative stress.
- The study analyzed serum levels of pro-inflammatory cytokines (IFN-, IL-1, and IL-6) in 33 AA patients, 30 NSV patients, and 30 healthy controls, using the ELISA method.
- Elevated levels of these cytokines were found in both conditions, with IL-6 significantly higher in NSV patients compared to those with AA, suggesting a link between oxidative stress and inflammation in both diseases.
Article Abstract
Alopecia areata (AA) and vitiligo are both common skin diseases of autoimmune origin. Both alopecia areata and vitiligo have shown to be affected by oxidative stress. The present work is aimed at evaluating and comparing the serum proinflammatory cytokine levels in AA and nonsegmental vitiligo (NSV). A cross-sectional study was conducted of 33 patients with AA, 30 patients with NSV, and 30 healthy controls. Serum levels of interferon (IFN-), interleukin- (IL-) 1, and IL-6 were determined quantitatively by ELISA method. Our analysis identified a of associated with AA and NSV, characterized by elevated levels of IFN- (AA: = 0.007283; NSV: = 0.038467), IL-1 (AA; NSV: ≤ 0.001), and IL-6 (AA; NSV: ≤ 0.001). IL-6 was also significantly increased in NSV patients in comparison with AA patients ( = 0.004485). Our results supported the hypothesis that oxidative stress may play a significant role in promoting and amplifying the inflammatory process both in AA and vitiligo. The complex understanding of both disease etiopathogenesis involves interrelationships between oxidative stress and autoimmunity. The clinical study registration number is RNN/266/16/KE.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7421748 | PMC |
| http://dx.doi.org/10.1155/2020/5693572 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Pathogenesis and regenerative therapy in vitiligo and alopecia areata: focus on hair follicle.
Front Med (Lausanne)
January 2025
Department of Dermatology, Institute of Regenerative Medicine, Affiliated Hospital of Jiangsu University, Zhenjiang, China.
Vitiligo is an autoimmune disease characterized by the loss of functional melanocytes in the hair follicles and epidermis, leading to white patches on the skin and mucous membranes. Alopecia areata (AA) is a common immune-mediated condition in which autoimmune attack on hair follicles cause non-scarring hair loss. Both diseases significantly impact patients's physical and mental health.
View Article and Find Full Text PDFRelapse of Alopecia Areata Responders After Tofacitinib Withdrawal: A Retrospective Study of 59 Patients.
J Cutan Med Surg
January 2025
Hu Nan Key Laboratory of Aging Biology, Department of Dermatology, Xiangya Hospital, Central South University, Changsha, China.
Dietary Measures as an Adjunctive Therapy in Alopecia Areata: A Scoping Review.
Clin Exp Dermatol
January 2025
Department of Dermatology, University of British Columbia, Vancouver, BC, Canada.
Baricitinib Provides Significant Improvements in Quality of Life and Functioning in Adults with Moderate-to-Severe Atopic Dermatitis with Baseline Body Surface Area ≤ 40% and Severe Itch.
Dermatol Ther (Heidelb)
January 2025
Department of Dermatology, University of Tsukuba, Tsukuba, Japan.
Introduction: Patients with moderate-to-severe atopic dermatitis (AD), a body surface area (BSA) of ≤ 40%, and an itch numerical rating scale (NRS) score of ≥ 7 ("BARI itch dominant") have been characterized as an important group to consider for the oral janus kinase (JAK) 1/2 inhibitor baricitinib (BARI). Herein we aim to evaluate quality of life (QoL) and functioning outcomes in adult patients with BSA ≤ 40% and itch NRS ≥ 7 at baseline (BL) who received BARI 4 mg in the topical corticosteroid (TCS) combination trial BREEZE-AD7.
Materials: BREEZE-AD7 was a randomized, double-blind, placebo-controlled, parallel-group outpatient study involving adult patients with moderate-to-severe AD who received once-daily placebo or 2-mg or 4-mg BARI in combination with TCS for 16 weeks.
Comparing the Efficacy of Combined Intralesional Triamcinolone Acetonide With Topical Calcipotriol Versus Intralesional Triamcinolone Acetonide Monotherapy in Scalp and Beard Alopecia Areata: Results From a Randomized Single-Blinded Clinical Trial.
J Cutan Med Surg
January 2025
Department of Dermatology, Venereology and Leprology, Sundaram Hospital, Trichy, Tamil Nadu, India.
Background: Intralesional (IL) steroids are the first-line treatment option for localized alopecia areata (AA). The present study aimed to compare the efficacy of topical calcipotriol with IL triamcinolone acetonide versus IL triamcinolone acetonide alone in AA.
Methods: This randomized single-blinded clinical trial was conducted in a dermatology outpatient department.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!